drugset / Trial / NCT03100630

Compare Bioavailability of RO7239361 After Subcutaneous Injection

NCT03100630 ↗

Phase 1 Completed 99 enrolled Hoffmann-La Roche
RandomizedParallel-groupOpen-labelOther

Summary

Randomized study in healthy men and women. Assess the similarity of RO7239361 when injected into the arm, thigh, or the stomach. Collect data on safety of RO7239361.

Timeline

Start
2017-05-09
Primary completion
2017-10-17
Completion
2017-10-17

Drugs

EvaluationDrugModalityDoseRoute
Comparator Taldefgrobep Alfa Protein / enzyme biologic — Subcutaneous

Indications

No indication recorded.